A Study Comparing Dexcom Continuous Glucose Monitoring to Point of Care Glucose Testing for the Management of Hospital and Post-Discharge Subjects With Type 1 Diabetes
Recruiting now · Not applicable
Conditions studied: Type 1 Diabetes
In brief
This study aims to compare inpatient glycemic control by measuring the percentage of time in the range of 70-180 mg/dl and the frequency of hypoglycemia between Dexcom G7 Continuous Glucose Monitoring (CGM) and Point of Care (POC) Blood Glucose Testing in poorly controlled subjects with Type 1 Diabetes Mellitus. The main question it aims to answer is: -Whether there is a difference between POC testing (standard of care) and Real-time CGM in glycemic control and hypoglycemic events during hospitalization:
Key facts
- Study ID
- NCT06752928
- Run by
- Emory University
- People needed
- 100
- Starts
- 2025-05-12
- Expected to finish
- 2026-10-01
- Last updated by the study team
- 2025-10-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Known history of T1D treated with insulin therapy (human regular or rapid-acting analogs or ultra-rapid analogs [lispro, aspart, glulisine, fast-acting insulin aspart, insulin lispro]), intermediate-acting (NPH and premixed formulations) or long-acting basal (glargine, detemir, degludec) formulations.
- Admission diagnosis of T1D with poorly controlled diabetes (blood glucose > 180 mg/dl, HbA1c > 7%), including diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS).
- Expected length of hospital stay > three days at the time of randomization
You may not qualify if…
- Patients admitted to the ICU
- Subjects using CGM technology before admission
- Subjects with type 2 diabetes
- Treatment with systemic immunosuppressive agents
- Cystic fibrosis
- Prisoners
- Patients expected to require MRI procedures during hospitalization.
- Female subjects who are pregnant or breastfeeding at enrollment into the study.
- Subjects not willing to wear a CGM device
- Subjects with clinically relevant hepatic disease (diagnosed liver cirrhosis and portal hypertension) and end-stage kidney disease (eGFR< 30 ml/min), or terminal illness.
- Subjects with a history of cognitive impairment, dementia, or mental condition rendering the subject unable to understand the nature and consequences of the study
Where it is running
- Grady Memorial Hospital — Atlanta, Georgia, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.